ProfileGDS5678 / 1428658_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 95% 95% 95% 93% 94% 96% 95% 95% 95% 94% 95% 95% 95% 95% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 18.3872395
GSM967853U87-EV human glioblastoma xenograft - Control 28.3736995
GSM967854U87-EV human glioblastoma xenograft - Control 38.3664295
GSM967855U87-EV human glioblastoma xenograft - Control 48.0163593
GSM967856U87-EV human glioblastoma xenograft - Control 58.3454494
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 18.5822996
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 28.2630395
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 38.4330795
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 48.2480995
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 18.2864894
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 28.3938695
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 38.3560495
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 48.3298295
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 58.4958595